CSL Secures Co-Development Rights for Alentis Fibrosis Drug in $1.55B Deal
CSL has agreed to pay $355 million upfront and up to $1.2 billion in milestones to co-develop and co-commercialize Alentis Therapeutics' phase 2 fibrosis drug, lixudebart. The deal grants CSL 55% of profits and funding for trials in kidney and liver diseases, including a phase 3 study for antineutrophil cytoplasmic antibodies-associated vasculitis.
Key points
- CSL will pay $355 million upfront for rights to lixudebart, an anti-Claudin-1 drug targeting fibrosis.
- CSL may pay up to $1.2 billion in additional commercial milestones if the drug reaches the market.
- Profit sharing is set at 55% for CSL and 45% for Alentis.
- CSL will fund the completion of the ongoing phase 2 study for AAV-RPGN, which showed promising kidney function improvements in 26 patients.
- The deal includes funding for a phase 3 trial in AAV-RPGN and phase 2 studies for focal segmental glomerulosclerosis and primary sclerosing cholangitis.
Background
This acquisition aligns with CSL's recent strategic shift following a profit slump and a CEO change earlier in 2026. The company already markets several nephrology drugs, including Mircera, Retacrit, Velphoro, and Korsuva. Alentis was previously recognized as a leader in Claudin-1 research, a protein associated with advanced liver fibrosis, in 2025.
How outlets are covering it
Fierce Biotech emphasizes the financial structure, highlighting the 55/45 profit split and the specific clinical data from the interim analysis of 26 patients. Endpoints News focuses on the total potential deal value, noting the $355 million upfront payment plus the $1.2 billion in future payments, but provides limited detail on the clinical indications due to paywall restrictions.
Why it matters
The partnership accelerates the development of lixudebart across multiple rare diseases, potentially offering new therapeutic options for kidney and liver conditions. It validates Claudin-1 as a therapeutic target and strengthens CSL's position in the global nephrology market.
What to watch
CSL will fund the completion of the phase 2 study for AAV-RPGN and initiate a phase 3 trial. Phase 2 studies for focal segmental glomerulosclerosis and primary sclerosing cholangitis are also planned.
- CSL pays $355M to co-develop Alentis’ phase 2-stage fibrosis drug Fierce Biotech
- CSL to pay $355M upfront to co-develop Alentis’ kidney and liver drug Endpoints News
- CSL Agrees to Pay Up to $1.6 Billion in Rare Disease Drug Deal Bloomberg.com
- CSL strikes $1.6B deal with Alentis for experimental kidney, liver drug (CSLLY:OTCMKTS) Seeking Alpha
- CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis reuters.com
Want the full story? Read the original reporting
Read on Fierce Biotech